Jon Isaacsohn, CinRx CEO
May 16, 2024 06:30 AM EDT
Financing
R&D

Ex­clu­sive: Gas­tro­pare­sis biotech Cin­Dome se­cures $40M for path to piv­otal tri­al

Kyle LaHucik

Senior Reporter

A gas­tro­pare­sis biotech from the cre­ator of Cin­Cor Phar­ma, the hy­per­ten­sion biotech bought by As­traZeneca for $1.8 bil­lion last year, has raised …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times